Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.48 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14617704 | 0.95 | ATM (0.64) | ATML3MBTL1LMNAPOLBMME | |
| SCHEMBL2034518 | 0.87 | PPID (0.58) | ATML3MBTL1POLBMMEACE | |
| SCHEMBL12643843 | 0.85 | ATM (0.64) | ATML3MBTL1POLBMMEACE | |
| SCHEMBL12643860 | 0.85 | MAPT (0.56) | ATML3MBTL1POLBMMEACE | |
| SCHEMBL15832199 | 0.84 | ATM (0.57) | ATML3MBTL1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL14617754 | 0.83 | ATM (0.64) | ATML3MBTL1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL2053665 | 0.81 | MAPT (0.51) | ATML3MBTL1MMEACECPA1 | |
| SCHEMBL16270324 | 0.80 | ATM (0.65) | ATML3MBTL1POLBSMN1; SMN2KLKB1 | |
| SCHEMBL14617723 | 0.79 | MME (0.56) | POLBTACR1MMEACECPA1 | |
| SCHEMBL15832201 | 0.77 | PPID (0.52) | ATML3MBTL1LMNAKLKB1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901295-B2 | Inhibitors of cyclophilins and uses thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-12-02 | — | — | US | disclosed |
| US-8802666-B2 | Inhibitors of cyclophilins and uses thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-06-26 | — | — | US | disclosed |
| US-20130018044-A1 | NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | FKBP3, FKBP4, FKBP5 | ATM 4698/4885L3MBTL1 3342/4885LMNA 4126/4885 |
| US-20130018044-A1 | NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF | FKBP3, FKBP4, FKBP5 | ATM 4698/4885L3MBTL1 3342/4885LMNA 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.